Ann: Bionomics' PTSD Trial Results, page-22

This must be a huge disappointment which has confounded those leading the trial.

But BNC210 was always seen as an improvement over benzodiazapenes and the latter have also proved to be fairly ineffective at treating PTSD.

The agitation trial in the elderly is more in line with what BNC210 was designed to do and I think it has a better chance of success there.

When the market calms down and analyses the result properly we may see a modest recovery.